Project 2: Strategies for Reducing Nicotine Content in Cigarettes

NCT ID: NCT02139930

Last Updated: 2018-08-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-09-30

Study Completion Date

2017-03-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main goal of this project is to compare two different approaches to reducing levels of nicotine in cigarettes: an immediate reduction in nicotine content in cigarettes to non-addictive levels or a gradual reduction in nicotine content in cigarettes to non-addictive levels. These two approaches will then be contrasted to a group that continues to smoke cigarettes with nicotine content similar to conventional cigarettes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This project will be conducted to compare product use patterns and biomarkers of exposure between smokers who are assigned to a) gradual reduction in reduced nicotine content (RNC) cigarettes; b) immediate reduction to very low nicotine content (VLNC) cigarettes or c) normal nicotine content (NNC) cigarettes. The outcomes from this study will provide information on different approaches to reducing levels of nicotine in cigarettes and will determine the approach with the most optimal outcomes taking into account the balance between overall risk reduction (possibly maximized by abrupt switching) and compliance and acceptability (possibly maximized by gradual reduction of RNC cigarettes).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nicotine Dependence Tobacco Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Normal Nicotine Control Group

These subjects will smoke normal nicotine content Spectrum brand cigarettes for 20 weeks.

Group Type ACTIVE_COMPARATOR

Normal Nicotine Control Group

Intervention Type BEHAVIORAL

Participants will smoke experimental cigarettes for a period of 20-weeks.

Immediate Nicotine Reduction Group

This group will immediately be switched to smoking very low nicotine content (VLNC) Spectrum brand cigarettes. They will smoke these cigarettes for 20 weeks.

Group Type EXPERIMENTAL

Immediate Nicotine Reduction Group

Intervention Type BEHAVIORAL

Participants will smoke experimental cigarettes for a period of 20-weeks.

Gradual Nicotine Reduction Group

This group will smoke progressively lower nicotine content Spectrum brand cigarettes for a period of one month each until they end up smoking the same VLNC cigarettes as the immediate reduction group.

Group Type EXPERIMENTAL

Gradual Nicotine Reduction Group

Intervention Type BEHAVIORAL

Participants will smoke experimental cigarettes for a period of 20-weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Normal Nicotine Control Group

Participants will smoke experimental cigarettes for a period of 20-weeks.

Intervention Type BEHAVIORAL

Immediate Nicotine Reduction Group

Participants will smoke experimental cigarettes for a period of 20-weeks.

Intervention Type BEHAVIORAL

Gradual Nicotine Reduction Group

Participants will smoke experimental cigarettes for a period of 20-weeks.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age 18+
2. Daily smokers who smoke an average of at least five cigarettes per day for at least 1 year
3. Breath CO levels \> 8 ppm (if ≤ 8 ppm, then NicAlert Strip level must indicate regular smoking)

Exclusion Criteria

1. Planned quit date in the next 30 days
2. Currently seeking treatment for smoking cessation
3. Currently using nicotine replacement therapies or other pharmacotherapies as cessation aid (non-cessation intermittent use acceptable)
4. A quit attempt in the past 30 days resulting in greater than 3 days of abstinence
5. Using other tobacco products or e-cigarettes more than 9 days in the past 30 days
6. Significant unstable medical conditions (Any significant change in a serious medical condition occurring during the past 3 months including, cardiovascular disease, COPD, and cancer, as determined by the licensed medical professional at each site)
7. Unstable psychiatric conditions (Any significant change in psychiatric symptoms during the past 3 months as determined by the licensed medical professional at each site)
8. Schizophrenia and schizoaffective disorder
9. Psychiatric medication changes (e.g., new prescriptions, changes in dosages, or discontinuation of medications) in the past 3 months that was a result of negative changes in symptoms.
10. Positive toxicology screen for any of the following drugs: cocaine, opiates, methadone, benzodiazepines, barbiturates, amphetamines, methamphetamines, and PCP

1. Marijuana will be tested for but will not be an exclusionary criterion.
2. Participants with valid prescriptions for opiates, benzodiazepines, barbiturates, amphetamines or methadone will not be excluded.
3. Participants failing the toxicology screen will be allowed to re-screen once.
11. Blood alcohol level \> 0.01

a. Participants failing the blood alcohol screen will be allowed to re-screen once.
12. Binge drinking alcohol (more than 9 days in the past 30 days, 4/5 drinks per day (female/male))
13. Pregnant, trying to become pregnant or breastfeeding
14. Predominant use of 'roll your own cigarettes'
15. CO reading \>80 ppm
16. Systolic BP greater than or equal to 160

a. Participants failing for blood pressure will be allowed to re-screen once.
17. Diastolic BP greater than or equal to 100

a. Participants failing for blood pressure will be allowed to re-screen once.
18. Systolic BP below 90 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)

a. Participants failing for blood pressure will be allowed to re-screen once.
19. Diastolic BP below 50 and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)

a. Participants failing for blood pressure will be allowed to re-screen once.
20. Heart rate greater than or equal to 105 bpm

a. Participants failing for heart rate will be allowed to re-screen once.
21. Heart rate lower than 45 bpm and symptomatic (dizziness, extreme fatigue, difficulty thinking, inability to stand or walk, feeling faint)

a. Participants failing for heart rate will be allowed to re-screen once.
22. Indicating any suicidal ideation in the past month, suicide attempts in the past 5 years (if within past 5 to 10 years, requires physician approval), or score of \>4 on the MINI suicide subscale
23. Household member enrolled in the study concurrently.
24. Inability to independently read and comprehend the consent form and other written study materials and measures because participants are required to complete parts of the protocol at home independently.
25. Participated in prior study that involved reduced nicotine content cigarettes.
26. Having participated in a research study during the past three months in a study that would impact baseline smoking or response to study products.
27. Currently taking the following anticonvulsant medications:

1. Phenytoin \[Brand Name: Dilantin\]
2. Carbamazepine \[Brand Name: Tegretol, Carbatrol, Equetro, Epitol\]
3. Oxcarbazepine \[Brand Name: Trileptal\]
4. Primidone \[Brand Name: Mysoline\]
5. Phenobarbital
28. Currently taking the following medication:

1. Bendamustine (Treanda)
2. Clopidogrel (Plavix)
3. Clozapine (Clozaril, FazaClo)
4. Erlotinib (Tarceva)
5. Flecainide (Tambocor)
6. Fluvoxamine (Luvox)
7. Irinotecan (Camptosar)
8. Olanzapine (Zyprexa)
9. Ropinirole (Requip)
10. Tacrine (Cognex)
11. Theophylline (Theo Dur, etc.)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute on Drug Abuse (NIDA)

NIH

Sponsor Role collaborator

Wake Forest University Health Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric Donny, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Pittsburgh

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mayo Clinic

Phoenix, Arizona, United States

Site Status

University of California San Francisco

San Francisco, California, United States

Site Status

Moffitt Cancer Center

Tampa, Florida, United States

Site Status

Johns Hopkins University

Baltimore, Maryland, United States

Site Status

University of Minnesota Medical School Duluth

Duluth, Minnesota, United States

Site Status

University of Minnesota

Minneapolis, Minnesota, United States

Site Status

Duke University

Durham, North Carolina, United States

Site Status

Oregon Research Institute

Eugene, Oregon, United States

Site Status

University of Pennsylvania

Philadelphia, Pennsylvania, United States

Site Status

MDAnderson Cancer Center

Houston, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Hatsukami DK, Luo X, Jensen JA, al'Absi M, Allen SS, Carmella SG, Chen M, Cinciripini PM, Denlinger-Apte R, Drobes DJ, Koopmeiners JS, Lane T, Le CT, Leischow S, Luo K, McClernon FJ, Murphy SE, Paiano V, Robinson JD, Severson H, Sipe C, Strasser AA, Strayer LG, Tang MK, Vandrey R, Hecht SS, Benowitz NL, Donny EC. Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA. 2018 Sep 4;320(9):880-891. doi: 10.1001/jama.2018.11473.

Reference Type DERIVED
PMID: 30193275 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

U54DA031659

Identifier Type: NIH

Identifier Source: secondary_id

View Link

U54 DA031659-P2

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Early Tobacco Abstinence - 5
NCT00224965 TERMINATED PHASE1